GSK plc 13F Holdings · Q2 2026
GSK plc reported 13 securities worth $602.22M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: CRSP (29.17%), WVE (17.60%), VIR (14.47%).
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | CRSP | CRISPR THERAPEUTICS AG | $175.7M | 29.17% | 3.2M | Hold |
| 2 | WVE | WAVE LIFE SCIENCES LTD | $106.0M | 17.60% | 18.2M | Hold |
| 3 | VIR | VIR BIOTECHNOLOGY INC | $87.1M | 14.47% | 8.6M | Hold |
| 4 | BNTX | BIONTECH SE | $82.8M | 13.75% | 889,824 | Hold |
| 5 | IDYA | IDEAYA BIOSCIENCES INC | $49.7M | 8.25% | 1.3M | Hold |
| 6 | CYTK | CYTOKINETICS INC | $29.0M | 4.82% | 340,434 | Hold |
| 7 | LYEL | LYELL IMMUNOPHARMA INC | $21.3M | 3.53% | 1.5M | Hold |
| 8 | SPRO | SPERO THERAPEUTICS INC | $20.3M | 3.37% | 9.2M | Hold |
| 9 | NKTX | NKARTA INC | $8.9M | 1.48% | 3.2M | Hold |
| 10 | FULC | FULCRUM THERAPEUTICS INC | $6.5M | 1.09% | 1.8M | Hold |
| 11 | BCYC | BICYCLE THERAPEUTICS PLC | $6.5M | 1.08% | 1.5M | Hold |
| 12 | CVRX | CVRX INC | $5.2M | 0.86% | 1.0M | Hold |
| 13 | RGNX | REGENXBIO INC | $3.3M | 0.54% | 271,456 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR